Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

RAS inhibition: probably not a one-size-fits-all approach

Nature Reviews Nephrology volume 5, pages 669–670 (2009)Cite this article

Blockade of the renin–angiotensin system does not seem to prevent early nephropathy in individuals with type 1 diabetes who are normoalbuminuric and normotensive, but both the angiotensin-converting-enzyme inhibitor enalapril and the angiotensin-receptor blocker losartan seem to retard retinopathy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mauer, M. et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 361, 40–51 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Mauer, S. M. et al. Structural–functional relationships in diabetic nephropathy. J. Clin. Invest. 74, 1143–1155 (1984).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cooper, M. E. et al. Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat. Diabetologia 32, 326–328 (1989).

    Article  CAS  PubMed  Google Scholar 

  4. Ruggenenti, P. et al. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 351, 1941–1951 (2004).

    Article  CAS  PubMed  Google Scholar 

  5. Patel, A. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829–840 (2007).

    Article  CAS  PubMed  Google Scholar 

  6. Bilous, R. et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann. Intern. Med. 151, 11–20 (2009).

    Article  PubMed  Google Scholar 

  7. Mann, J. F. et al. Effects of telmisartan on renal outcomes: a randomized trial. Ann. Intern. Med. 151, 1–10 (2009).

    Article  PubMed  Google Scholar 

  8. Chaturvedi, N. et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351, 28–31 (1998).

    Article  CAS  PubMed  Google Scholar 

  9. Chaturvedi, N. et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 372, 1394–1402 (2008).

    Article  CAS  PubMed  Google Scholar 

  10. Wilkinson-Berka, J. L., Tan, G., Jaworski, K. & Miller, A. G. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ. Res. 104, 124–133 (2009).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes Division, Baker IDI Heart and Diabetes Institute, JDRF Danielle Alberti Center for Diabetic Complications, Melbourne, Australia

    Drazenka Pongrac Barlovic & Mark E. Cooper

Authors
  1. Drazenka Pongrac Barlovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark E. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark E. Cooper.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barlovic, D., Cooper, M. RAS inhibition: probably not a one-size-fits-all approach. Nat Rev Nephrol 5, 669–670 (2009). https://doi.org/10.1038/nrneph.2009.189

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2009.189

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing